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ABSTRAK 
  
Pendarahan yang teruk adalah salah satu faktor penyumbang kematian di 
dunia. Rawatan dalam keadaan pendarahan teruk adalah penting bagi mengembalikan 
hemostasis pesakit. Beberapa intervensi pernah digunakan untuk menghentikan 
perdarahan dengan kadar keberkesanan, keselamatan dan keputusan yang 
berbeza. Salah satu daripada agen hemostasis novel ialah recombinant activated factor 
VII (rFVIIa). Pelbagai kontroversi terhadap penggunaan rFVIIa sebagai salah satu 
pilihan untuk untuk rawatan pendarahan dalam kalangan pesakit bukan 
hemofilia. Tujuan kajian ini dijalankan adalah untuk menyelidik penggunaan rFVIIa 
secara luar indikasi dalam kalangan pesakit yang menagalami pendarahan yang teruk 
di Hospital Universiti Sains Malaysia.  
Rekod perubatan 76 pesakit bukan penghidap hemofilia yang dirawat dengan 
menggunakan rFVIIa untuk pendarahan, sepanjang tempoh 11 tahun di institusi 
tunggal yang menggunakan rFVIIa dalam rawatan dikaji untuk indikasi rawatan, 
kematian dalam masa 24 jam dan 30 hari, keperluan transfusi dan profil 
pembekuan. Pesakit dikelaskan kepada trauma, selepas bersalin, lain-lain pembedahan 
dan masalah kesihatan lain. Risiko masalah thromboembolism dinilai dalam kalangan 
pesakit.  
Pesakit masalah kesihatan lain adalah yang paling banyak menggunakan 
rFVIIa diikuti oleh trauma, lain-lain pembedahan, dan paling sedikit diberikan kepada 
pesakit selepas bersalin. Secara keseluruhan, setiap kategori mencatatkan kurang 
daripada 25% risiko kematian dalam masa 24 jam manakala pelbagai peratusan untuk 
kematian pada hari ke-30. Komponen dan produk darah (sel kejap, plasma beku segar, 
platelet, cryoprecipitate) yang diperlukan adalah berkurangan setelah pesakit 
 ix 
 
menerima rFVIIa. Terdapat juga perubahan profil pembekuan (prothrombin time, 
activated partial thromboplastin time, international normalized ratio) pada pesakit 
sebelum dan selepas dirawat dengan rFVIIa. Tiada komplikasi thromboembolism 
dicatatkan dalam kajian ini. Kepentingan statistik telah dinilai pada p <0.05.  
Penggunaan rFVIIa adalah efisien dalam memberi kesan yang cepat untuk 
merawat pendarahan yang teruk. Pesakit yang dirawat dengan rFVIIa menunjukkan 
pengurangan keperluan transfusi komponen dan produk darah. Selain itu, 
penambaikan yang ketara dalam parameter pembekuan juga dapat diperhati dalam 
kalangan pesakit bukan hemophilia di Hospital Universiti Sains Malaysia. Kajian ini 
mendapati rFVIIa tidak mempunyai kaitan dengan komplikasi thromboembolism 
selepas pembedahan. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
 
ABSTRACT 
 
Massive bleeding has been a one of the contributing causes of death in the 
world. It is crucial for physicians to establish haemostasis during this condition. 
Currently, there are various type of methods to arrest bleeding with different 
efficiency, safety profile and outcome. One of the novel haemostatic agent is 
recombinant activated factor VII (rFVIIa). There has been a considerable controversy 
on usage of rFVIIa as one of the option to stop bleeding among non-haemophiliac 
patients. The aim of this study is to determine the outcome of off-label use of rFVIIa 
to treat bleeding among the non-haemophiliac patients in Hospital Universiti Sains 
Malaysia.  
Medical records of 76 non-haemophiliac patients treated with rFVIIa for 
desperate bleeding over 11-year period at the single institution administering rFVIIa 
were recorded for treatment indications, 24-hours and 30-day mortality, transfusion 
need and coagulation profiles. The patients were classified into trauma, post-partum, 
other surgery and medical. Complication of thromboembolism events are assessed 
among patients.  
rFVIIa are most administered in medical patients followed by trauma, other 
surgery and post-partum. Overall, each category reported less than 25% risk of 24-
hour mortality while various percentage for mortality at day-30. Blood and blood 
products (packed red blood cell, fresh frozen plasma, platelet, cryoprecipitate) needed 
are significantly reduced in patients receiving rFVIIa. There is also improvement of 
coagulation profiles (prothrombin time, activated partial thromboplastin time, 
international normalized ratio) in patients before and after treated with rFVIIa. None 
 xi 
 
of thromboembolism events described for this study. Statistical significance was 
assessed at p<0.05.  
rFVIIa therapy is efficient for immediate response for those suffering from 
massive haemorrhage. Patients received rFVIIa were less likely to require further 
packed cells and blood product transfusion. It was accompanied by a significant 
improvement in measurement of coagulation parameters. rFVIIa was not associated 
with incidence of postoperative thromboembolism in this study.  
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CHAPTER ONE 
INTRODUCTION 
 
 
 
1.1 BACKGROUND OF THE STUDY 
Worldwide population including Malaysians are aware of many health conditions 
that can lead to disability and death. The situations that usually come across their minds 
are cancer, heart disease, stroke, physical-related injuries such as road traffic accidents, 
and infectious diseases. Being least known, bleeding also contributes to one of the 
common causes of death. Severe cases of uncontrolled bleeding may lead to shock, 
circulatory failure or serious complication from treatment such as circulatory overload or 
transfusion related acute lung injury (Sahu et al., 2014) .  
Bleeding is a condition that take place when blood leaks from blood vessel and are 
being drawn out from the circulatory system. A serious condition happens when bleeding 
occur internally since it is usually being ignored or unrecognised. It can also occur 
externally through a natural opening such as from the mouth, nose, ear, urethra, vagina, 
anus, or a break in the skin. Typically, a healthy person can tolerate a loss of 10 to 15% 
of total blood volume (García, 2009). One who experiences a large amount of blood loss 
is considered as massive bleeding.  
Massive bleeding is a condition where patients need to be transfused with more 
than 10 units of packed red cells (Meissner and Schlenke, 2012). It is a challenging 
situation for haematological and blood transfusion services as pressure may arise in order 
to stop the bleeding, supply blood products and provide laboratory services. 
Approximately one-third of all bleeding trauma patients are accompanied with a 
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coagulopathy upon admission to hospital (Frith et al., 2010). These situations increased 
the incidence of multiple organ failure and death significantly compared to patients with 
similar injury patterns in the absence of a coagulopathy. According to Spahn et al. (2013), 
massively bleeding trauma patient needs early identification of bleeding sources, prompt 
measures to minimise blood loss, restore tissue perfusion and haemodynamic stability. 
Apart from mechanical compression at the source of bleeding, transfusion of blood 
products is one of the standard therapies for any massive bleeding cases. To date, there 
are a few pharmacological inventions available to facilitate haemostasis such as 
prothrombin complex concentrate (PCC), tranexamic acid, and recombinant activated 
factor VII (rFVIIa). However, each choices of treatment has their significant benefits and 
limitations (Elshamaa and Elokda, 2015). Due to uncertainty about the benefits and risks 
of these interventions, this study was initiated to survey the outcome of one of these 
options i.e. rFVIIa in the treatment of massive bleeding.  
rFVIIa is a human plasma-derived activated factor VII which was produced by 
utilising recombinant technology. It is a novel prohaemostatic agent, normally 
administered intravenously under physicians supervision. It is commercially and widely 
used in the management of haemophilia patients with inhibitors. To date, the use in non-
haemophiliac patients has remained off-label. Some of these off-label indications of 
rFVIIa are cardiac surgery, trauma, liver transplantation, obstetric haemorrhage and liver 
cirrhosis has been well-reported (Lin et al., 2012). As a procoagulant agent, the main 
concern is the risk of thromboembolism. Thus, thus study is also aiming to observe the 
thromboembolic occurrence among patients who had been treated with rFVIIa. 
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1.2 RESEARCH OBJECTIVES 
1.2.1  General Objective: 
 To assess the treatment indications, clinical outcome, transfusion need and 
coagulation profiles of non-haemophiliac patients receiving rFVIIa during 
massive bleeding in Hospital Universiti Sains Malaysia (HUSM). 
 
1.2.2  Specific Objectives: 
 To study the changes in blood product requirement in 24 hours before and after 
administration of rFVIIa in massive bleeding patient in HUSM. 
 To study the changes of coagulation profile before and after administration of 
rFVIIa during massive bleeding in HUSM. 
 To describe the outcome of mortality and thromboembolic complication of 
patients received rFVIIa in HUSM. 
 
 
1.3       STUDY HYPOTHESIS 
 Blood product requirements are significantly reduced after administration of 
rFVIIa in massive bleeding patient in HUSM. 
 There is significant improvement of coagulation profiles in massive bleeding 
patients in HUSM after administration of rFVIIa. 
 Massive bleeding patients in HUSM who received rFVIIa have better outcome in 
term of survival and thromboembolic complication. 
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1.4 JUSTIFICATION OF THE STUDY 
Massive haemorrhage is a possible preventable cause of mortality and morbidity. 
Thus, it is a serious decision to be make in the massive bleeding management. Correct 
decision plays an important role in the massive bleeding management. Decision must be 
quick, proper and accurate because any adverse events may be irreversible.  
The optimal resuscitative plan on type of fluid, volume, rate, route of 
administration, prohaemostatic medications and outcome of resuscitation during massive 
bleeding remains a debate (Alam and Velmahos, 2011). Sometimes, they may introduce 
adverse events that are unpredictable or unrecognised post-operatively.  
As a consequence, there have been numerous initiatives that aim to improve 
outcome and prevent complication among the massive bleeding patients. Year by year, 
haemostatic intervention are evolving and novel drug such as rFVIIa has been introduced. 
However, there have been discrepancies in the outcome of rFVIIa among massive 
bleeding patients. The usage to treat bleeding for non-haemophiliac patients is still 
debatable. Therefore, this study may contribute to the literature on the outcome of usage 
of rFVIIa in non-haemophiliac massive bleeding management in Hospital Universiti Sains 
Malaysia.  
To date, most of the data were contributed by the developed countries. The authors 
aimed to share the research outcome on off-label rFVIIa usage in a developing country ie. 
Malaysia. 
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CHAPTER TWO 
  LITERATURE REVIEW 
2.1 MASSIVE BLEEDING 
Massive blood loss is defined as loss of one blood volume within 24-hour period. 
Alternatively, it can also be defined as loss of 50% blood volume within 3 hours or a rate 
of blood loss of at least 150 ml/min (Stainsby et al., 2000). Major surgery related to 
cardiovascular, liver, major traumas and oral anti-coagulant therapy are the most common 
causes of excessive blood loss (Franchini et al., 2008).  Treatment strategies of 
postoperative bleeding comprise of supportive care with volume resuscitation, blood 
products administration, intervention of pharmacology and surgical re-exploration 
(Soliman et al., 2012). Failure to recognise bleeding and commencement of an appropriate 
prompt management is one of the leading cause of preventable death following trauma. A 
multidisciplinary approach to the prompt recognition of shock due to haemorrhage 
following trauma is important preferentially before the decompensation. 
Massive bleeding events have enormous effect and may potentially deteriorate 
patients’ prognosis and outcomes. Few advancements have been made for understanding 
of the pathophysiology of trauma, the availability of diagnostic adjuncts and the 
introduction of new resuscitation protocols (Curry et al., 2011). Even then, the outcome 
from massive haemorrhage remain poor most of the time in regards to massive transfusion 
and significant coagulopathy. 
Massive bleeding requiring massive transfusion can occur in any clinical 
conditions and almost always associated with significant mortality and morbidity. Volume 
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replacement such as fluid and blood product transfusion are the first few essential 
constituents of the management of patients with massive bleeding. The degree of efficacy 
of these therapeutic interventions should outweigh potential risks.  
 
2.1.1     Effect of Massive Bleeding 
Trauma patients with severe bleeding involve an entangled and crucial 
management for the medical practitioners. Even though much effort has been put in to 
understand the pathophysiology of bleeding, the mortality rate remains high. The priority 
of acute phase of haemorrhage is to arrest the bleeding as quickly as possible by involving 
fluid resuscitation, blood component transfusion and vasopressors usage (Bougle et al., 
2013). According to Meissner and Schlenke (2012), trauma contributes to one of the most 
common causes of death for individuals between the age of 18 and 45 when it is supposed 
to be the most productive years in life. In agreement with Curry et al. (2011) and  Panteli 
et al. (2015), this situation represent 40% of mortality and the most common cause of 
preventable death.  
 
2.1.2 Management of Massive Bleeding 
During a severe haemorrhage episode, the top priority is to stop bleeding instantly. 
If this bleeding is not controlled, there will be continuous deterioration of patient, causing 
circulatory failure, tissue hypoxia and organ dysfunction. It may be helped by surgery, 
volume replacement, blood products transfusions and pharmacological 
interventions(Martinez-Calle et al., 2016). 
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2.1.2.1 Surgery 
Constant haemorrhage in trauma patients may gain benefit from emergency 
surgery if the elapsed time between injuries to hospital admission is minimized (Cothren 
et al., 2007). During surgery, the bleeder will be first identified. Clamps and pressure will 
be applied to slow down the bleeding. If an organ is severely injured causing uncontrolled 
bleeding, it can sometimes be removed to stop the bleeding, for example by splenectomy, 
nephrectomy, partial hepatectomy, hysterectomy or even limbs amputation. Subsequently, 
electrical cautery can be used to burn and stop the bleeding from small vessels. Bleeding 
vessels can also be identified and tied with sutures (Thomas et al., 2016). 
 However, some cases of uncontrolled bleeding is unable to be treated by surgery.  
This include pulmonary haemorrhage and disseminated intravascular coagulopathy due to 
amniotic fluid embolism or severe sepsis (Shetty et al., 2015).  
 
2.1.2.2 Fluid Replacement  
 Bouglé et al. (2013) concluded that first therapeutic intervention for haemorrhagic 
shock is fluid resuscitation. The choice of fluid depends on the patient’s conditions and 
physician’s consensus. However, there is no written literature on the supremacy of one 
type of fluid over another in trauma patients. For example, in a case of brain tumor 
resection, excessive blood loss may happen. Extensive transfusion of crystalloid or colloid 
has a tendency of causing volume overload and brain swelling (Vesel et al., 2015b). 
Too much of crystalloid or colloid infusion may also lead to dilution of coagulation 
factors causing consumptive coagulopathy, hypothermia and metabolic acidosis (Nguyen 
et al., 2009). This may lead to the worsening of the diffuse bleeding.  
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Crystalloids are solutions of minerals and other water-soluble molecules. Both 
water and electrolytes will cross semi-permeable membrane into the interstitial space and 
achieve equilibrium in 2 to 3 hours. 3mL of isotonic crystalloid solution are needed to 
replace 1mL of patient blood optimally. This is because approximately 2/3 of solution will 
leave the vascular space in 2 to 3 hours. On the other hand, colloid are large molecular 
weight solutions with weight of more than 30 kDaltons. They are macromolecular 
substances made of gelatinous and do not readily cross the semi-permeable membranes. 
The advantages that colloids have over crystalloids is that the colloids can induce a more 
rapid and persistent volume expansion because of a greater increase in oncotic pressure 
(Lundsgaard-Hansen and Pappova, 1981).  
Large volumes of crystalloids may relate to tissue oedema, abdominal 
compartment syndrome (Madigan et al., 2008), and hyperchloremic metabolic acidosis 
(Handy and Soni, 2008). On the other hand, too much of colloids may easily cause 
circulatory overload which is hard to be reserved using diuretic medications. Current 
findings on comparison between colloids and crystalloids in Cochrane review (Perel et al., 
2013) reported that there is no solid proof that colloids administration reduced mortality 
risk as compared to crystalloids in patients with trauma, burns, or after surgery. One 
possible postulation is, both of these fluid are not the ideal replacement during 
haemorrhage. 
 
2.1.2.3 Blood and Blood Products Transfusions  
Massive bleeding management remains challenging as the patient has high 
potential to get into haemostatic failure leading to fatal outcome. Alternative strategies to 
treat bleeding are vital as several approaches proposed to decrease blood loss have 
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unpredictable degrees of success and complication rate. Basic regime to achieve 
haemostasis in severe bleeding cases comprise of blood and blood components 
administration. The conservative treatments include administration of packed red blood 
cells (pRBC), fresh frozen plasma (FFP), cryoprecipitate or fibrinogen, and platelet 
concentrates. However, large volume of blood products transfusion are linked to the 
transfusion adverse reactions such as infections, hypothermia, disseminated intravascular 
coagulopathy, excessive fibrinolysis, dilutional coagulopathy, and metabolic acidosis, 
which may worsen bleeding and morbidity (Vasudev et al., 2016).  This is supported by 
Engoren et al. (2002) that transfusion is associated with a 70% increase in disability and 
death in postoperative cardiac surgery after correction for confounding factors and 
comorbidities.   
Occurrence of transfusion transmitted diseases (TTI) is proven low but the risk is 
still there especially when there is involvement of numerous number or blood bag 
transfusion. The most unwanted adverse event of blood transfusion is transfusion-related 
acute lung injury (TRALI) even though its prevalence is much lower (~1:10,000) than 
other adverse effects such as febrile or allergy reactions (~1%) (Otsubo and Yamaguchi, 
2008).  
Early administration of FFP and pRBCs in massive bleeding had been proven to 
prevent severe dilutional coagulopathy and contributed to survival improvement of 
patients. However, large amount of further blood components administration may put the 
patient at risk of Transfusion Associated Cardiac Overload (TACO) (Naveen and Ajju, 
2014). 1 to 1.5 units of FFP must be given per unit of pRBC to correct the dilutional 
component of coagulation alone. Sequel of anaemia, thrombocytopenia, and an increase 
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of the volume overload may accompanied with imbalance of FFP: pRBC ratio (Spahn et 
al., 2013).  
A study by Hunt (2014) stated that there is still lack of strong quality on evidence 
of usage of blood components to treat massive bleeding.  Administration of blood 
components routinely in critical care practice from decades ago are still in shortfall since 
there’s lack of study being carried out.  
 
2.1.2.4 Pharmacological Interventions 
Advancement of understanding in pathophysiology of haemorrhage has led to 
improvement of pharmacological interventions for resuscitation strategies. There are a 
few commonly used drugs in Malaysia which was utilised to treat bleeding with variable 
safety and efficacy profile. Some interventions are frequently used to uncontrolled 
bleeding patients, such as tranexamic acid and Vitamin K.  
Tranexamic acid is an antifibrinolytic agent. It is a synthetic lysine derivative 
which acts by inhibiting conversion of plasminogen to plasmin. Thus, it helps to reduce 
the degree of fibrinolysis. It has been successfully incorporated into most trauma 
management plans due to its low risk of complication. However, the onset is slow thus it 
should be given prior to surgery (Kietpeerakool et al., 2016). 
Vitamin K or known as phytonadione is also a drug with a haemostasis property. 
It is commonly used in the prevention of haemorrhagic disease of newborn. It is 
administered orally or intravenously to reverse the anticoagulant effects of warfarin 
through promoting the production of clotting factors II, VII, IX and X. Usage of Vitamin 
K in patients ongoing warfarin treatment with an INR of 4.5 to 9.9 without bleeding is not 
recommended (Crowther et al., 2009) . It is given by intravenous slowly to avoid severe 
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hypotension and rare anaphylactic reactions (Riegert-Johnson and Volcheck, 2002). It has 
a good potential in maintaining coagulation homeostasis in the body. However, due to the 
slow onset, it is still being used as a supplementary intervention during acute severe 
bleeding (Marti-Carvajal et al., 2008). 
PCC is a concentrated product of plasma with a variety of clotting factors. It was 
initiated to replace Factor IX in haemophilia B patients. Nowadays, this product is well-
known for Vitamin K reversal therapy. It is suggested to use PCC over FFP for patients 
with massive bleeding while receiving ongoing Vitamin K therapy (Sorensen et al., 2011). 
However, the product labelling does include a caution of possibilities of developing 
arterial and venous thrombotic complications associated with its use (Product 
Information: KCENTRA Intravenous Powder, 2013). 
Calcium alginate possesses  haemostatic capacity that can be utilised as local 
haemostatic agent and wound dressing (Qin, 2004). When calcium alginate make a 
contacts with tissue, calcium and sodium ions are exchanged and form a gel. However, 
the complications at the injury site is unknown (Taskin et al., 2013).  
Aprotinin is one of the powerful antifibrinolytic agents that works as serine 
protease inhibitor. Its most important effect is to inhibit plasmin, trypsin and kallikreins. 
It is usually given as prophylactic in patients having vascular surgery to prevent bleeding. 
However, it is very costly and associated to several side effects such as hypersensitivity 
reactions related to repeated exposure (Porte and Leebeek, 2002). It is also prone to cause 
thrombosis to the patients. It was withdrawn from the market since 2008 (Chee et al., 
2016) and not available in Malaysia.  
Protamine sulphate is used to reverse the effects of heparin but may accompanied 
with few adverse effects including hypotension, hypersensitivity and paradoxical 
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anticoagulation with excessive doses (Park, 2004). The potential risk factors for adverse 
events to protamine included previous exposure, rate of administration, vasectomy and 
fish allergy (Porsche and Brenner, 1999).  
Desmopressin is a synthetic analogue of the antidiuretic hormone vasopressin 
(Leissinger et al., 2014). Its raises plasma levels of factor VIII (FVIII) and von Willebrand 
factor (VWF), tissue plasminogen activator (t-PA), and also has vasodilator effect. The 
release of multimer VWF enhances binding to the subendothelial matrix and platelets. 
Consequently, increases haemostatic efficacy (Kaufmann and Vischer, 2003). 
Nevertheless, administration of desmopressin commonly cause headache, facial flushing, 
mild hypotension and tachycardia. However, many patients treated repeatedly over a short 
time period become less responsive to these therapy (Franchini, 2007) .  
2.2 COAGULATION CASCADE  
 
Figure 2.1: Coagulation cascade  
(Hoffbrand and Moss, 2011) 
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Three main parts of coagulation cascade in the body are extrinsic pathway, 
intrinsic pathway and common coagulation pathway. In case of injury to the blood vessel, 
tissue factor is brought into contact with naturally occurring activated factor VIIa (FVIIa), 
forming a complex of TF-FVIIa which then activates FIX and FX. FXa and its co-factor 
FVa form the prothrombinase complex, which convert prothrombin to thrombin. 
Conversion of prothrombin to thrombin is the common coagulation pathway. Later, 
thrombin convert fibrinogen to fibrin to form a localised stable clot (David et al., 2009).   
The intrinsic pathway initiated with the formation of complex on collagen by high-
molecular-weight kininogen (HMWK), prekallikrein, and FXII (Hageman 
factor). Prekallikrein is converted to kallikrein and FXII becomes FXIIa. Then, FXIIa 
converts FXI into FXIa. Factor XIa converts FX to FXa and continues with common 
pathway for clot formation at site of injury (Pallister and Watson, 2010).  
 
2.3 CONFOUNDING FACTORS FOR BLEEDING AND COAGULOPATHY 
Different clinical presentation of the patient such as hypothermia and acidosis can 
contribute to the outcome of haemostasis treatment. Hypothermia and acidosis were 
reported to influence coagulopathy in different clinical settings .There is significant 
numbers of mortality in patients with massive haemorrhage with hypothermia, acidosis 
and coagulopathy. They are known as “lethal triad” (Cosgriff et al., 1997). The outcomes 
of massive haemorrhage are still poor even though many advancement has been uncovered 
in regards to the pathophysiology and management of trauma. This may be related to 
presence of confounding factors in patients. However, the variables are closely linked and 
cannot be assessed individually in a clinical setting. 
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2.3.1 Lethal triad  
 
Figure 2.2: Lethal triad, (Gerecht, 2014) 
 
The known “lethal triad” and their well-established contributing role in morbidity 
and mortality of trauma consists of coagulopathy, acidosis and hypothermia (Smith et al, 
2013; Faraoni and Van Der Linden, 2014). Understanding of the pathophysiology of the 
lethal triad with rapid recognition should serve as the basis for the management of the 
bleeding trauma patient. 
Coagulopathy is any disorder related to the blood coagulation. Coagulopathy 
related to shock and blood loss has a multifactorial aetiology including consumption of 
clotting factors, platelets and haemodilution. Additionally, hyperfibrinolysis, 
hypothermia, acidosis and metabolic changes may also affect the coagulation system. 
Adrien et al. (2013) reported that the priority goals for early resuscitation of haemorrhage 
is for the improvement and prevention of coagulopathy. Development of traumatic 
coagulopathy involves a few mechanism such as consumption of coagulation factors and 
platelets due to bleeding, haemodilution secondary to overzealous fluid resuscitation and 
overactivation of coagulation owing to haemorrhage injury. Acute coagulopathy is 
another contributing factor for mortality and morbidity following trauma (Spahn et al., 
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2013). Thrombin generation, fibrin formation and serum fibrinogen concentration are 
reduced in acute coagulopathy. This may lead to increased transfusion requirement and 
mortality in bleeding patients (Faraoni and Van Der Linden, 2014).  
Acidosis occurred as a result of tissue hypoperfusion and presence of excess 
chloride. The condition may impair activities of plasma protease, coagulation factor 
complexes and cell surface interactions. Moreover, acidosis may stunt the thrombin and 
clotting factors production. Drop of pH from 7.4 to 7.0 decreases the action of factor VIIa 
by 90%, factor VIIa/ tissue factor complex formation by 55% and factor Xa/Va complex 
formation by 70%. Acidosis should be avoided as coagulation cascade need an optimal 
range of pH to function well. For instance, there is 10% a reduction of enzymatic activity 
of factor VIIa at pH 7.0 instead of 7.4 (Chee et al., 2016). It is also supported by Meng et 
al. (2003) that reduction in the pH to 7.0 nearly eliminates efficacy of rFVIIa activity. 
Hypothermia may cause impairment coagulation in whole blood. The coagulation 
function is compromised by hypothermia and acidosis synergistically (Dirkmann et al., 
2008). Hypothermia can lead to obstructions of protease activity and platelet function. 
Therefore, upper body warm blankets are used by patients in the emergency room or 
intensive care unit (ICU) to prevent cooling down (Smith et al., 2013). Additionally, to 
avoid hypothermia, the transfused intravenous fluids and blood components should be 
warmed to 37 °C.  It is considered as mild hypothermia when the core body temperature 
is 32°C to 35°C, moderate at 28°C to 32°C, and severe when the core body temperature 
is below 28°C. Severe trauma related to hypothermia has been associated with 100% 
mortality. A decrease in temperature can reduce the activity of FVIIa and platelets 
linearly. Moreover, unconscious or sedated patients are always associated with 
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hypothermia which leads to reduce in clotting enzyme activity and decrease in platelet 
function. This process worsens the coagulopathy (Smith et al., 2013). 
This triad worsen the haemorrhage and may eventually leads to death. Research 
suggested correction of hypothermia, acidosis and coagulopathy in trauma is necessary as 
much as considerations of surgical management. In order to manage critically ill trauma 
patients, a firm understanding on the lethal triad is essential (Beekley, 2008). 
 
2.3.2 Underlying conditions 
Different group of patients may portray different categories of risk factor for 
bleeding. This include pregnancy, patient taking blood thinning agent, patients with liver 
failure or patients with hereditary haematological abnormality. 
Pregnancy is hypercoagulable state. This condition might be a confounding factor 
in the treatment with rFVIIa. In normal adults, mean level of plasma FVIIa is 3.6 ng/mL 
at the range between 0.5 to 8.4 ng/mL with variation between individuals.  The levels may 
be elevated in pregnancy cases and reduced with oral anticoagulant therapy (Fong, 1997). 
A reproductive studies of rats and rabbits treated with rFVIIa at 6 mg/kg and 5 mg/kg 
doses revealed that the dose is not associated with mortality and abortion rate. Besides, no 
sign of teratogenicity was observed after treatment. Nevertheless, treatment of pregnant 
women with rFVIIa should only be proposed with risk outweigh risk to the foetus. There 
is also no adverse reaction reported during labour, vaginal delivery and tubal ligation when 
the doses of 36 μg/kg and 90 μg/kg were given. Excellent response between 80% to 95% 
in obstetrical and gynaecological situations were observed with rFVIIa administration 
(Madhusudan et al., 2017). 
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2.3.3 Previous medication  
Patients on treatment with antiplatelet, warfarin or heparin may have an impact on 
the haemostasis when given rFVIIa. One of the example of antiplatelet is aspirin which 
believed to cause a significant increase in blood product in cardiac surgery. Aspirin is the 
drug that is responsible to the interference of platelet aggregation and adhesion. Thus, it 
modify the haemostasis of postoperative which lead to excessive blood transfusion (Victor 
et al., 2011). Warfarin which is the Vitamin K antagonist work by inhibiting the vitamin 
K epoxide reductase. Hence the reusing of inactive vitamin K epoxide back to the active 
reduced form. This result in exhaustion of active form Vitamin K that is needed for arrest 
bleeding (Ufer, 2005).  
 
2.3.4 Liver Failure 
Hepatic parenchymal cells in liver plays a major role in haemostasis as the place 
to synthesis the coagulation factors, anticoagulant proteins and components of the 
fibrinolytic system. The reticuloendothelial system of the liver aids in coagulation and 
fibrinolysis by eliminating coagulation factors from the circulation. As liver is a highly 
vascularised organ with vital venous systems draining through the parenchyma, any liver 
diseases can affect blood flow and cause bleeding problems. Abnormal liver function can 
resulted from various aetiology such as impairment of coagulation factor synthesis, 
synthesis of dysfunctional coagulation factors, overconsumption of coagulation factors, 
deformed clearance of activated coagulation factors and quantitative and qualitative 
platelet disorders (Faybik et al., 2006).  
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2.3.5 Hereditary bleeding disorder  
The most common hereditary disorder of haemostasis is von Willebrand 
disease (VWD) while the most common hereditary coagulation disorders are haemophilia. 
VWD is a heterogeneous haemorrhagic disorder caused by a deficiency or dysfunction of 
the protein called von Willebrand factor (vWF). Deformed vWF interaction between 
platelets and the vessel wall meddling with primary hemostasis in the body. In term of 
coagulation profiles, Haemophilia A and B always has a prolonged aPTT with normal 
platelets and PT. It is diagnosed with spontaneous joints bleeding, excessive bruising, 
menorrhagia, unexplained epistaxis and prolonged bleeding after minor cuts, minor 
surgery or dental procedures (Crookston et al, 2016). 
 
2.4 RECOMBINANT ACTIVATED FACTOR VII 
Recombinant activated factor VII (rFVIIa; Novo Nordisk, Bagsvaerd, Denmark) 
is a novel haemostatic agent act by activating the extrinsic pathway of the coagulation 
cascade. It was originally developed for the management of bleeding in haemophilia A 
and B patients with inhibitors to factor VIII or IX by bypassing the intrinsic pathway of 
coagulation cascade. 
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Fig 2.3: Recombinant activated factor VII (rFVIIa) as a bypassing haemostatic           
agent 
 
It is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues 
(MW 50 kDa). rFVIIa is secreted into the culture media which contain newborn calf serum 
in its single-chain form and then proteolytically converted by autocatalysis to the active 
two-chain form during a chromatographic purification process. The process has been 
demonstrated to remove exogenous viruses.  It is produced by using recombinant DNA 
technology which is from factor VII cDNA transfected into kidney of baby hamsters and 
purified by series of chromatography steps, involving immunoaffinity chromatography 
using murine monoclonal antibodies. It is structurally similar to human plasma-derived 
Factor VIIa and none of material are extracted from human is used started from 
production, processes and final product thus it is unlikely to have risk on infectious agents 
compared to blood products. rFVIIa is presented in glass vials containing 1.2 mg, 2.4 mg 
and 4.8 mg. It is supplied as a sterile, white lyophilized powder of rFVIIa in single-use 
vials.  
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Each vial of lyophilized drug contains the following: 
 Contents  1.2 mg (60 KIU) 
Vial  
2.4 mg (120 KIU) 
Vial  
4.8 mg (240 KIU) 
Vial  
rFVIIa  1200 μg  2400 μg  4800 μg  
sodium chloride*  5.84 mg  11.68 mg  23.36 mg  
calcium chloride dihydrate*  2.94 mg  5.88 mg  11.76 mg  
glycylglycine  2.64 mg  5.28 mg  10.56 mg  
polysorbate 80  0.14 mg  0.28 mg  0.56 mg  
mannitol  60.0 mg  120.0 mg  240.0 mg  
* per mg of rFVIIa: 0.44 mEq sodium, 0.06 mEq calcium  
 
The  action of rFVIIa is limitedly used at the site of injury and exposed tissue 
factor, thus the risk of systemic activation of coagulation system is almost unlikely to take 
place (Vesel et al., 2015a). rFVIIa induce haemostasis at optimum doses at injury site by 
creating complexes with exposed tissue factor and by binding to activated platelet surface. 
It generates thrombin through direct activation of factor X (Hoffman et al., 1998). It is 
administered intravenously according to body weight. rFVIIa should not be 
simultaneously administered with infusion solutions. 
 
2.4.1 Pharmacodynamics 
rFVIIa involves in extrinsic clotting pathway where it forms a complex with tissue 
factor which in the presence of calcium and phospholipids activates coagulation factor X 
which then initiates the conversion of prothrombin into thrombin at the site of injury 
(Figure 2.1). Formation of thrombin and clot stabilises platelet plug and form a tight fibrin 
structure which is resistant to lysis. This process may also occur on the surface of activated 
platelets. 
